Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: Sunovion
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• non-smoking males and non-pregnant females greater than or equal to 18 years of age

• forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) greater than or equal to 80% of predicted values

• normal systolic and diastolic blood pressures

Exclusion Criteria:

• history of heart disease, irregular heartbeat, hypertension

• history of diabetes, hyperthyroid

• history of pneumonia, tuberculosis

• history of seizure disorder, depression, hospitalization in the last month for non-elective purposes, cold or flu in the previous three months